Teyi Pharmaceutical Group Co.Ltd(002728) 3 issued the annual report of 2021 on March 15. During the reporting period, the company achieved an operating revenue of 7581605 million yuan, a year-on-year increase of 19.83%; The net profit attributable to the shareholders of the listed company was 1269174 million yuan, a year-on-year increase of 189.66%.
In 2021, the company focused on the development of varieties of Chinese patent medicines. While expanding its core products, the company increased the market cultivation and development of potential Chinese patent medicines. The sales revenue of Chinese patent medicines was 3244713 million yuan, a year-on-year increase of 64.69%. The sales of zhikebao tablets, the company’s core product, recovered well and reached the expectation.
The gross profit margin of the company’s proprietary Chinese medicine products is relatively high, which has led to the overall improvement of the company’s comprehensive gross profit margin, and the performance has increased significantly year-on-year.
